The Pyoderma Gangrenosum drugs in development market research report provides comprehensive information on the therapeutics under development for Pyoderma Gangrenosum, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Pyoderma Gangrenosum. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Pyoderma Gangrenosum - Drugs In Development, 2023

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Pyoderma Gangrenosum and features dormant and discontinued products.

GlobalData tracks five drugs in development for Pyoderma Gangrenosum by five companies/universities/institutes. The top development phase for Pyoderma Gangrenosum is preclinical with three drugs in that stage. The Pyoderma Gangrenosum pipeline has five drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Pyoderma Gangrenosum pipeline products market are: BioMarck Pharmaceuticals, Bristol-Myers Squibb and InflaRx.

The key targets in the Pyoderma Gangrenosum pipeline products market include Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B), Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5), and Myristoylated Alanine Rich C Kinase Substrate (Protein Kinase C Substrate 80 kDa Protein Light Chain or PKCSL or MARCKS).

The key mechanisms of action in the Pyoderma Gangrenosum pipeline product include Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) Inhibitor with one drug in Phase III. The Pyoderma Gangrenosum pipeline products include six routes of administration with the top ROA being Intravenous and three key molecule types in the Pyoderma Gangrenosum pipeline products market including Monoclonal Antibody, and Small Molecule.

Pyoderma Gangrenosum overview

Pyoderma gangrenosum (PG) is one of a group of autoinflammatory disorder neutrophilic dermatoses. PG generally starts with a small bump resembling a spider bite that can rapidly enlarge, forming a very painful ulcer. It is usually associated with autoimmune diseases like ulcerative colitis, Crohn’s disease, and arthritis. It is diagnosed by its characteristic appearance and severe pain. Biopsy can be helpful in ruling out other causes of ulceration. Small ulcers are treated with topical steroid ointment, special dressings, oral anti-inflammatories, and antibiotics. Large ulcers can be treated with oral prednisolone, ciclosporin, baricitinib, and biological agents like infliximab, adalimumab, and etanercept.

For a complete picture of Pyoderma Gangrenosum’s pipeline drug market, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.